{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:46Z","timestamp":1794011446692,"version":"4.8.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising therapeutic efficacy in relapsed or refractory (R\/R) multiple myeloma. However, distinct CAR T-cell constructs exhibit varying therapeutic outcomes. As the antigen-recognition domain, nanobodies offer a small, stable, single-domain structure with enhanced affinity and specificity compared with conventional single-chain variable fragments. We explored the use of nanobody-based BCMA(S103) CAR T-cell therapy for R\/R plasma cell myeloma. The CAR construct incorporates dual-nanobody variable domain of the heavy chain of heavy chain antibody (VHHs) targeting BCMA. A cohort of 27 patients was treated with S103 CAR T-cell therapy, which included 4 patients of plasma cell leukemia, and 1 patient of anaplastic plasma cell myeloma. Eleven patients had multiple extramedullary lesions, and 11 patients exhibited high-risk genetic abnormalities, including 4 with TP53 mutations. One month after CAR T-cell infusion, the overall response rate (ORR) was 96.3% (26\/27), with a complete response (CR) + very good partial response (VGPR) rate of 59.2% (16\/27). At the 3-month follow-up, the ORR increased to 100% (27\/27), with a CR + VGPR rate of 81.5% (22\/27). The median duration of remission was 11 months (range, 2-36 months). The 1-year overall survival rate was 61.1%, and progression-free survival was 57.2%. In conclusion, BCMA CAR T-cell therapy, utilizing dual-nanobody VHHs targeting BCMA, demonstrates a high ORR and manageable safety profile in treating patients with R\/R plasmacytic myeloma, including those with high-risk features such as extramedullary lesions, high-risk cytogenetic abnormalities, plasma cell leukemia, or anaplastic plasmacytoma. This trial was registered at www.ClinicalTrials.gov as #NCT04447573.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016322","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:56:07Z","timestamp":1750938967000},"page":"4543-4552","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-2190","authenticated-orcid":false,"given":"Xian","family":"Zhang","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"3Hebei Senlang Biotechnology Co, Ltd, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona N.","family":"Hu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina N.","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoge","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"3Hebei Senlang Biotechnology Co, Ltd, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Wang","sequence":"additional","affiliation":[{"name":"3Hebei Senlang Biotechnology Co, Ltd, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7369","authenticated-orcid":false,"given":"Pei H.","family":"Lu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"},{"name":"2Lu Daopei Institute of Hematology, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"13","key":"2026100109362423700_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2026100109362423700_bib2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2026100109362423700_bib3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100109362423700_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"2026100109362423700_bib5","unstructured":"Abecma (idecabtagene vicleucel). Bristol Myers Squibb; 2021. Accessed 9 December 2024. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf."},{"key":"2026100109362423700_bib6","unstructured":"Carvykti (ciltacabtagene autoleucel). Janssen Biotech; 2022. Accessed 9 December 2024. https:\/\/www.fda.gov\/media\/156560\/download."},{"issue":"4","key":"2026100109362423700_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/imt-2017-0136","article-title":"Emerging immune targets for the treatment of multiple myeloma","volume":"10","author":"Sohail","year":"2018","journal-title":"Immunotherapy"},{"issue":"2","key":"2026100109362423700_bib8","doi-asserted-by":"crossref","first-page":"e12910","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scand J Immunol"},{"issue":"1","key":"2026100109362423700_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"2026100109362423700_bib10","doi-asserted-by":"crossref","first-page":"101\u2009141","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK cells in multiple myeloma: expanding the targets","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2026100109362423700_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"2026100109362423700_bib12","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2026100109362423700_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2026100109362423700_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"2026100109362423700_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fimmu.2018.00273","article-title":"Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment","volume":"9","author":"Iezzi","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2026100109362423700_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"Biomark Res"},{"key":"2026100109362423700_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","article-title":"Exploiting nanobodies' singular traits","volume":"36","author":"Ingram","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2026100109362423700_bib18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2026100109362423700_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","article-title":"Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents","volume":"334","author":"Sharifzadeh","year":"2013","journal-title":"Cancer Lett"},{"issue":"8","key":"2026100109362423700_bib20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026100109362423700_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"2026100109362423700_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","author":"Lou","year":"2022","journal-title":"Cancer Commun"},{"issue":"4","key":"2026100109362423700_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2026100109362423700_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2026100109362423700_bib25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2026100109362423700_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2026100109362423700_bib27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2026100109362423700_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2026100109362423700_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2026100109362423700_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2026100109362423700_bib31","doi-asserted-by":"crossref","first-page":"106\u2009687","DOI":"10.1016\/j.leukres.2021.106687","article-title":"Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment","volume":"111","author":"Gowin","year":"2021","journal-title":"Leuk Res"},{"issue":"7","key":"2026100109362423700_bib32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1080\/10428194.2016.1250263","article-title":"Plasma cell leukemia: update on biology and therapy","volume":"58","author":"Mina","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026100109362423700_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/path.2692","article-title":"Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice","volume":"221","author":"Qi","year":"2010","journal-title":"J Pathol"},{"issue":"10","key":"2026100109362423700_bib34","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1002\/hed.26818","article-title":"Rare case of anaplastic plasmacytoma in the sinonasal tract","volume":"43","author":"Xing","year":"2021","journal-title":"Head Neck"},{"issue":"22","key":"2026100109362423700_bib35","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4543\/2411512\/blooda_adv-2025-016322-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4543\/2411512\/blooda_adv-2025-016322-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:16:08Z","timestamp":1790864168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4543\/537958\/Efficacy-and-safety-of-BCMA-nanobody-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016322","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,10]]}}}